Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 2/20 | 0.36 |
| ▸ | FGF2 | P09038 | 3/20 | 0.34 |
| ▸ | FGF1 | P05230 | 2/20 | 0.34 |
| ▸ | VEGFA | P15692 | 2/20 | 0.34 |
| ▸ | HPSE | Q9Y251 | 2/20 | 0.34 |
| ▸ | NT5E | P21589 | 1/20 | 0.34 |
| ▸ | BCHE | P06276 | 4/20 | 0.33 |
| ▸ | MDK | P21741 | 1/20 | 0.33 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.32 |
| ▸ | ANTXR2 | P58335 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4404462 | 0.88 | LMNA (0.42) | SLC6A2FGF2FGF1VEGFAHPSE | |
| SCHEMBL4407362 | 0.88 | FGF2 (0.40) | SLC6A2FGF2FGF1VEGFAHPSE | |
| SCHEMBL4404804 | 0.87 | BCHE (0.41) | BCHEPTPN1ANTXR2 | |
| SCHEMBL4402910 | 0.85 | FGF2 (0.41) | SLC6A2FGF2FGF1VEGFAHPSE | |
| SCHEMBL4403642 | 0.84 | FGF1 (0.38) | FGF2FGF1VEGFAHPSENT5E | |
| SCHEMBL4409916 | 0.83 | PTPN1 (0.38) | BCHEPTPN1ANTXR2 | |
| SCHEMBL4402915 | 0.82 | FGF1 (0.39) | SLC6A2FGF2FGF1VEGFAHPSE | |
| SCHEMBL4402919 | 0.82 | PTPN1 (0.38) | BCHEPTPN1 | |
| SCHEMBL26562238 | 0.76 | PAX8 (0.38) | PTPN1 | |
| SCHEMBL15965619 | 0.76 | TYMP (0.40) | SLC6A2FGF2FGF1VEGFAHPSE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8173606-B2 | Sulfated oligosaccharide derivatives | PROGEN PHARMACEUTICALS LIMITED (AU) | 2012-05-08 | — | — | US | disclosed |
| US-20110130354-A1 | SULFATED OLIGOSACCHARIDE DERIVATIVES | PROGEN PHARMACEUTICALS LIMITED (AU) | 2011-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110130354-A1 | SULFATED OLIGOSACCHARIDE DERIVATIVES | HPSE, APOB, LIPG | SLC6A2 4286/4885FGF2 166/4885FGF1 348/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.